ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the second quarter of 2023.
- Topline data from the company’s ongoing Phase 2 randomized, placebo-controlled study of neffy in urticaria patients are expected by the fourth quarter of 2023.
- R&D Expenses: Research and development (R&D) expenses were $7.3 million for the quarter ended June 30, 2023.
- G&A Expenses: General and administrative (G&A) expenses were $13.3 million for the quarter ended June 30, 2023.
- Net Loss: Net loss was $17.4 million for the quarter ended June 30, 2023.